Cargando…

Patient Preferences for Treatment of Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: A Cross-country Choice Experiment

BACKGROUND: Patients with non–muscle-invasive bladder cancer (NMIBC) that is unresponsive to bacillus Calmette-Guérin (BCG) immunotherapy face a difficult choice. Immediate radical cystectomy (RC) is effective but might represent overtreatment. Continuing bladder preservation with medical therapy is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Collacott, Hannah, Krucien, Nicolas, Heidenreich, Sebastian, Catto, James W.F., Ghatnekar, Ola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Bladder Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974996/ https://www.ncbi.nlm.nih.gov/pubmed/36874596 http://dx.doi.org/10.1016/j.euros.2022.12.016

Ejemplares similares

Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
por: Tan, Wei Shen, et al.
Publicado: (2023)

A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
por: Kulkarni, Girish S., et al.
Publicado: (2022)

Partial Versus Complete Bacillus Calmette-Guérin Intravesical Therapy and Bladder Cancer Outcomes in High-risk Non–muscle-invasive Bladder Cancer: Is NIMBUS the Full Story?
por: Rezaee, Michael E., et al.
Publicado: (2021)

Quality of Life in Patients with High-grade Non–muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial
por: van Straten, Christine G.J.I., et al.
Publicado: (2023)

The Use of Urine Mycobacterium tuberculosis Complex Polymerase Chain Reaction as a Predictive Factor for Recurrence and Progression After Intravesical Bacillus Calmette-Guérin Therapy in Patients with Non–muscle‑invasive Bladder Cancer
por: Muto, Satoru, et al.
Publicado: (2021)

Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
por: Cooper, Owen Alan Edwards, et al.
Publicado: (2023)

Treatment and disease management patterns for bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer in North America, Europe and Asia: A real-world data analysis
por: Broughton, Edward I., et al.
Publicado: (2022)

Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer
por: Suh, Jungyo, et al.
Publicado: (2020)

Emerging treatments for bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer
por: Kim, Hyung Suk, et al.
Publicado: (2021)

Treatment strategies for the Bacillus Calmette-Guérin–unresponsive non-muscle invasive bladder cancer
por: Jeong, Seung-hwan, et al.
Publicado: (2023)

How to reduce bacillus Calmette-Guérin discontinuation in patients with severe functional impairment
por: Di Gianfrancesco, Luca, et al.
Publicado: (2022)

Defining Factors Associated with High-quality Surgery Following Radical Cystectomy: Analysis of the British Association of Urological Surgeons Cystectomy Audit
por: Tan, Wei Shen, et al.
Publicado: (2021)

Pyuria as a Predictive Marker of Bacillus Calmette–Guérin Unresponsiveness in Non-Muscle Invasive Bladder Cancer
por: Suh, Jungyo, et al.
Publicado: (2021)

Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment
por: Besançon, Marjorie, et al.
Publicado: (2022)

The Significant Role of Depression in Elderly Patients with Bladder Cancer
por: Oserowsky, Alexander, et al.
Publicado: (2021)

Renal Morbidity Following Radical Cystectomy in Patients with Bladder Cancer
por: Schmidt, Bogdana, et al.
Publicado: (2022)

Carboplatin Induction Chemotherapy in Clinically Lymph Node–positive Bladder Cancer
por: von Deimling, Markus, et al.
Publicado: (2023)

Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans
por: Kumar, Abhishek, et al.
Publicado: (2021)

Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non–muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial
por: Yu, Ge, et al.
Publicado: (2023)

Living with Bladder Cancer: Self-reported Changes in Patients’ Functional and Overall Health Status Following Diagnosis
por: Ungerer, Garrett, et al.
Publicado: (2020)

Morbidity and Days Alive and Out of Hospital Within 90 Days Following Radical Cystectomy for Bladder Cancer
por: Maibom, Sophia L., et al.
Publicado: (2021)

Human Gut Mycobiome and Fungal Community Interaction: The Unknown Musketeer in the Chemotherapy Response Status in Bladder Cancer
por: Bukavina, Laura, et al.
Publicado: (2022)

Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
por: Kool, Ronald, et al.
Publicado: (2021)

Development of the First Patient-centred Set of Outcomes for Muscle-invasive and Metastatic Bladder Cancer: A Multicentre Initiative
por: Reesink, Daan J., et al.
Publicado: (2021)

Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy
por: Hesswani, Charles, et al.
Publicado: (2023)

Trial-based Cost-effectiveness Analysis of an Immediate Postoperative Mitomycin C Instillation in Patients with Non–muscle-invasive Bladder Cancer
por: Hentschel, Anouk E., et al.
Publicado: (2022)

A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice
por: de Ruiter, Ben-Max, et al.
Publicado: (2022)

Pembrolizumab in bacillus Calmette-Guérin unresponsive nonmuscle-invasive bladder cancer; a difficult to treat disease (KEYNOTE-057)
por: Kumar, Bhuwan
Publicado: (2021)

Validation and Reliability Testing of the EORTC QLQ-NMIBC24 Questionnaire Module to Assess Patient-reported Outcomes in Non–Muscle-invasive Bladder Cancer
por: Blazeby, Jane M., et al.
Publicado: (2014)

SPTAN1, APC, and FGFR3 Mutation Status and APOBEC Mutation Signatures are Predictive of Mitomycin C Response in Non-muscle-invasive Bladder Cancer
por: Lindgren, Maria Skydt, et al.
Publicado: (2021)

Sexual Dimorphism in Outcomes of Non–muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint
por: Chenard, Stephen, et al.
Publicado: (2021)

Potential Carbon Savings with Day-case Compared to Inpatient Transurethral Resection of Bladder Tumour Surgery in England: A Retrospective Observational Study Using Administrative Data
por: Phull, Manraj, et al.
Publicado: (2023)

Bacillus Calmette-Guérin in the management of superficial bladder cancer
por: Kapoor, Rakesh, et al.
Publicado: (2008)

Predictive biomarkers of response to bacillus Calmette‐Guérin immunotherapy and bacillus Calmette‐Guérin failure for non‐muscle invasive bladder cancer
por: Wang, Ziting, et al.
Publicado: (2022)

Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2015)

FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer
por: Zhang, Yang, et al.
Publicado: (2022)

Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update
por: Guallar-Garrido, Sandra, et al.
Publicado: (2020)

Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer
Publicado: (2021)

Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2016)

Bacillus Calmette–Guérin Immunotherapy for Cancer
por: Cardillo, Fabíola, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eec51tqsok01juinpl3u601jp2